Are We Moving Toward Curative Approaches in Chronic Lymphocytic Leukemia?

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Chronic lymphocytic leukemia (CLL) management has shifted from chemoimmunotherapy to targeted oral inhibitors.
• Continuous Bruton tyrosine kinase (BTK) inhibition and time-limited BCL-2 therapy are now standard of care.

Purpose of the Study:

• To review the contemporary evidence, clinical recommendations, and future directions in targeted CLL management.
• To highlight the transformation of CLL treatment paradigms over the past decade.

Main Methods:

• Review of recent clinical trials and evidence.
• Summary of current clinical practice recommendations.
• Discussion of ongoing research in CLL therapeutics.

Main Results:

• Oral targeted inhibitors (e.g., ibrutinib, acalabrutinib, zanubrutinib, venetoclax) have improved survival and quality of life in CLL.
• Fixed-duration regimens with BCL-2 inhibitors achieve deep, measurable residual disease (MRD)-negative remissions.
• Combination therapies and MRD-guided treatment cessation show promise for durable, chemotherapy-free responses.

Conclusions:

• The current CLL management paradigm is individualized, driven by biomarkers (TP53, IGHV) and comorbidities.
• Treatment selection is tailored to patient fitness, tolerance, and long-term safety.
• Future directions include optimizing treatment sequencing, overcoming resistance, and integrating novel immunotherapies.